EUVIMEDEUVIMED entdecken
Crossref

Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells

Ai-Ling Su, Chang-Qing Tian, Ying-Jie Ou, Xu-Bin Bao, Xia-Juan Huan, Ze-Hong Miao, Ying-Qing Wang

Life Sciences · 2023

DOI: 10.1016/j.lfs.2023.122129 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Sciences, 2023. Verfasst von Ai-Ling Su und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Sha…. Hauptthemen laut MEDLINE: 5'-Nucleotidase, Proteasome Inhibitors, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Shanghai Institute of Materia Medica Chinese Academy of Sciences, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ecto-5'-nucleotidase (CD73), encoded by the NT5E gene, mediates tumor immunosuppression and has been targeted for the development of new anticancer drugs. Proteasome inhibitors impair protein degradation by inhibiting proteasome and have been used in the clinic for cancer therapy. Here we report that proteasome inhibitors reduce the protein and mRNA levels of CD73. Among 127 tested small-molecule drugs, proteasome inhibitors were found to consistently decrease the protein and mRNA levels of CD73 in NSCLC NCI-H1299 cells. This effect was further confirmed in different NSCLC cells exposed to different proteasome inhibitors. In those treated cells, the protein levels of ERK and its active form p-ERK, the vital components in the MAPK pathway, were reduced. Consistently, inhibitors of MEK and ERK, another two members of the MAPK pathway, also lowered the protein and mRNA levels of CD73. Correspondingly, treatments with fibroblast growth factor 2 (FGF2), an activator of the MAPK pathway, enhanced the levels of p-ERK and partly rescued the proteasome inhibitor-driven reduction of CD73 mRNA and protein in NSCLC cells. However, exogenous CD73 overexpression in murine Lewis lung carcinoma (LLC) cells was not lowered either in vitro or in vivo, by the treatments with proteasome inhibitors and basically, did not affect their in vitro proliferative inhibition either. In contrast, CD73 overexpression dramatically reduced the in vivo anticancer activity of Bortezomib in immunocompetent mice, with tumor growth inhibition rates from 52.18 % for LLC/vector down to 8.75 % for LLC/NT5E homografts. These findings give new insights into the anticancer mechanisms of proteasome inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

5'-NucleotidaseProteasome InhibitorsLung NeoplasmsCarcinoma, Non-Small-Cell LungExtracellular Signal-Regulated MAP KinasesHumansAnimalsMiceCell Line, TumorGPI-Linked ProteinsMice, Inbred C57BLGene Expression Regulation, NeoplasticRNA, MessengerMAP Kinase Signaling System

Stichwörter der Autor:innen

CD73ERKNSCLCProteasome inhibitors

Substanzen

5'-NucleotidaseProteasome InhibitorsNT5E protein, humanGPI-Linked ProteinsExtracellular Signal-Regulated MAP KinasesRNA, Messenger

Autor:innen und Institutionen

  • State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China; University of Chinese Academy of Sciences, No. 19…
  • State Key Laboratory of Drug Research, Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201203, China.

Förderung

  • Shanghai Institute of Materia Medica Chinese Academy of Sciences
  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality
  • State Key Laboratory of Drug Research, Chinese Academy of Sciences

Zitieren

APA

Su, A. L., Tian, C. Q., Ou, Y. J., Bao, X. B., Huan, X. J., Miao, Z. H., & Wang, Y. Q. (2023). Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells. Life Sciences. https://doi.org/10.1016/j.lfs.2023.122129

Vancouver

Su AL, Tian CQ, Ou YJ, Bao XB, Huan XJ, Miao ZH, et al. Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells. Life Sciences. 2023. doi:10.1016/j.lfs.2023.122129

BibTeX
@article{Su2023,
  author = {Su, Ai-Ling and Tian, Chang-Qing and Ou, Ying-Jie and Bao, Xu-Bin and Huan, Xia-Juan and Miao, Ze-Hong and Wang, Ying-Qing},
  title = {Proteasome inhibitors reduce CD73 expression partly via decreasing p-ERK in NSCLC cells},
  journal = {Life Sciences},
  year = {2023},
  doi = {10.1016/j.lfs.2023.122129}
}
Kostenlos starten →